The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Sep. 25, 2018

Filed:

Sep. 11, 2015
Applicant:

Novartis Ag, Basel, CH;

Inventors:

Winfried Elis, Munchen-Pasing, DE;

Seth Ettenberg, Melrose, MA (US);

Andrew Paul Garner, Arlington, MA (US);

Nicole Haubst, Munich, DE;

Xizhong Huang, Southborough, MA (US);

Christian Carsten Silvester Kunz, Munich, DE;

Elizabeth Anne Reisinger Sprague, Concord, MA (US);

Qing Sheng, Sharon, MA (US);

Assignee:

Novartis AG, Basel, CH;

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
C07K 16/00 (2006.01); A61K 39/395 (2006.01); C12P 21/08 (2006.01); C07K 16/32 (2006.01); A61K 45/06 (2006.01); A61K 31/4439 (2006.01); C07K 16/28 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
A61K 39/39558 (2013.01); A61K 31/4439 (2013.01); A61K 39/3955 (2013.01); A61K 45/06 (2013.01); C07K 16/28 (2013.01); C07K 16/2863 (2013.01); C07K 16/32 (2013.01); A61K 2039/505 (2013.01); A61K 2039/507 (2013.01); C07K 2317/21 (2013.01); C07K 2317/55 (2013.01); C07K 2317/73 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01);
Abstract

This invention relates to antibodies or fragments thereof which interact with HER family of receptors, e.g., HER3 receptor. In particular, it relates to antibodies or fragments thereof that recognize a conformational epitope of HER3 receptor comprising residues from both domains 2 and 4 resulting in inhibition of both ligand-dependent and ligand-independent signal transduction; and allow ligand binding (e.g., neuregulin), while preventing ligand-induced activation of signal transduction. These antibodies or fragments can be used to treat a number of diseases or disorders characterized by increased levels of HER3 expression (e.g., esophageal cancer). These antibodies or fragments can be used to treat a number of diseases or disorders characterized by the antibodys or fragments ability to decrease tissue weight (e.g., prostate or uterine weights) or to induce atrophy of tissue (e.g., atrophy of male breast).


Find Patent Forward Citations

Loading…